Altium Capital Management LLC Acquires Shares of 1,060,000 ImmunityBio, Inc. (NASDAQ:IBRX)

Altium Capital Management LLC acquired a new position in ImmunityBio, Inc. (NASDAQ:IBRX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 1,060,000 shares of the company’s stock, valued at approximately $2,714,000.

Several other large investors have also made changes to their positions in the company. Marshall Wace LLP bought a new position in ImmunityBio during the fourth quarter worth about $615,000. XTX Topco Ltd increased its stake in shares of ImmunityBio by 14.0% during the 4th quarter. XTX Topco Ltd now owns 105,883 shares of the company’s stock worth $271,000 after purchasing an additional 12,973 shares during the last quarter. Barclays PLC raised its stake in ImmunityBio by 9.8% in the fourth quarter. Barclays PLC now owns 396,484 shares of the company’s stock valued at $1,015,000 after buying an additional 35,448 shares during the period. Raymond James Financial Inc. bought a new stake in ImmunityBio in the 4th quarter valued at $172,000. Finally, Capula Management Ltd acquired a new position in ImmunityBio in the 4th quarter valued at about $154,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Stock Down 0.4 %

ImmunityBio stock opened at $2.47 on Friday. The company’s 50 day moving average price is $2.96 and its two-hundred day moving average price is $3.50. The stock has a market cap of $2.11 billion, a P/E ratio of -2.68 and a beta of 0.51. ImmunityBio, Inc. has a 52 week low of $2.28 and a 52 week high of $10.53.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.11. The company had revenue of $7.55 million during the quarter, compared to the consensus estimate of $8.74 million. On average, equities analysts anticipate that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on IBRX shares. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of ImmunityBio in a research note on Wednesday. BTIG Research assumed coverage on shares of ImmunityBio in a research report on Friday, January 10th. They issued a “buy” rating and a $6.00 target price on the stock. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $30.00 price objective on shares of ImmunityBio in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $12.19.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.